Human immunodeficiency virus type 1 mother-to-child transmission and prevention: successes and controversies

J Intern Med. 2011 Dec;270(6):561-79. doi: 10.1111/j.1365-2796.2011.02458.x. Epub 2011 Oct 27.

Abstract

The World Health Organization (WHO) and United Nations Programme on HIV/AIDS (UNAIDS) estimated that an additional 370 000 new human immunodeficiency virus type 1 (HIV-1) infections occurred in children in 2009, mainly through mother-to-child transmission (MTCT). Intrapartum transmission contributes to approximately 20-25% of infections, in utero transmission to 5-10% and postnatal transmission to an additional 10-15% of cases. MTCT accounts for only a few hundred infected newborns in those countries in which services are established for voluntary counselling and testing of pregnant women, and a supply of antiretroviral drugs is available throughout pregnancy with recommendations for elective Caesarean section and avoidance of breastfeeding. The single-dose nevirapine regimen has provided the momentum to initiate MTCT programmes in many resource-limited countries; however, regimens using a combination of antiretroviral drugs are needed also to effectively reduce transmission via breastfeeding.

MeSH terms

  • Adolescent
  • Anti-HIV Agents / therapeutic use
  • Breast Feeding
  • Cesarean Section
  • Drug Resistance, Viral / drug effects
  • Female
  • Guidelines as Topic
  • HIV Infections / prevention & control*
  • HIV Infections / transmission*
  • HIV-1 / pathogenicity*
  • Humans
  • Infant
  • Infant, Newborn
  • Infectious Disease Transmission, Vertical / prevention & control*
  • Pregnancy
  • Pregnancy Complications, Infectious / prevention & control*
  • Risk Factors
  • Time Factors
  • Young Adult

Substances

  • Anti-HIV Agents